Publications in collaboration with researchers from Hospital Miguel Servet (14)

2024

  1. Prognostic Value of Lymph Node Ratio in Patients with Uterine Carcinosarcoma

    Journal of Personalized Medicine, Vol. 14, Núm. 2

2023

  1. Oncological outcomes among young women with non-epithelial ovarian cancer: The YOC-Care study (Young Ovarian Cancer - Care)

    International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 915-921

  2. Prognostic factors in patients with uterine sarcoma: The SARCUT study

    International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 897-904

  3. Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme

    European Journal of Cancer, Vol. 182, pp. 3-14

2022

  1. Prospective Real-World Gynaecological Cancer Clinical Registry with Associated Biospecimens: A Collaborative Model to Promote Translational Research between GEICO and the Spanish Biobank Network

    Cancers, Vol. 14, Núm. 8

  2. Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study

    BMC Cancer, Vol. 22, Núm. 1

2021

  1. Elective Cancer Surgery in COVID-19-Free Surgical Pathways during the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study

    Journal of Clinical Oncology, Vol. 39, Núm. 1, pp. 66-78

  2. Preoperative nasopharyngeal swab testing and postoperative pulmonary complications in patients undergoing elective surgery during the SARS-CoV-2 pandemic

    British Journal of Surgery, Vol. 108, Núm. 1, pp. 88-96

2020

  1. The impact of secondary cytoreductive surgery on survival in first recurrence of platinum sensitive epithelial ovarian cancer

    European Journal of Gynaecological Oncology, Vol. 41, Núm. 4, pp. 523-530

2019

  1. Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer

    Anti-Cancer Drugs, Vol. 30, Núm. 6, pp. 628-635

2017

  1. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624

  2. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2008

  1. A phase II trial of fixed-dosed rate gemcitabine in platinum-resistant ovarian cancer: A GEICO (Grupo Español de Investigación en Cáncer de Ovario) trial

    American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 31, Núm. 5, pp. 481-487

2005

  1. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: A GEICO (Grupo Español de Investigación en Cáncer de Ovario) study

    Annals of Oncology, Vol. 16, Núm. 5, pp. 749-755